MolecularMD Announces Presentations at Four Upcoming Scientific Conferences

PORTLAND, OR--(Marketwired - Nov 6, 2013) - MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to oncology drug developers, announced today that it will be presenting a poster at each of four upcoming conferences: ASCO-EORTC-NCI Markers in Cancer, Circulating Nucleic Acids in Plasma and Serum (CNAPS VIII), Association for Molecular Pathology (AMP) Annual Meeting, and the 10th International Congress of the Society for Melanoma Research. 

The presentations cover topics that highlight MolecularMD's technical achievements in assay development addressing the challenges presented by the clinical need for comprehensive genotyping data using limited source material such as plasma circulating solid tumor DNA and FFPE biopsy tissue. 

Presentation Details:

Obtaining Maximal Information from Limited FFPE Tissue Specimens: Development and Validation of a 4-Gene Custom NGS Panel for a GIST Clinical Trial
ASCO-EORTC-NCI Markers in Cancer
November 7-9, Brussels, Belgium

Platform comparison for the detection of mutant DNA in the plasma of melanoma patients
Circulating Nucleic Acids in Plasma and Serum (CNAPS VIII)
November 7-8, Baltimore, MD
(Presentation by collaborators in the laboratory of Dr. David Polsky at NYU Medical Center)

FFPE DNA Quality: Impact on Downstream Performance in Molecular Diagnostic Assays
Association for Molecular Pathology (AMP) Annual Meeting
November 14-16, Phoenix, AZ

Liquid Biopsy: Analytical Validation of a Plasma-Based BRAF V600 AS-PCR Assay
10th International Congress of the Society for Melanoma Research
November 17-20, Philadelphia, PA

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Tests are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.